// App-Quantinova.ai

4098 : NeoHx study: Perioperative treatment with trastuzumab in combination with capecitabine and oxaliplatin (XELOX-T) in patients with HER2 resectable stomach or esophagogastric junction (EGJ) adenocarcinomaR0 resection, pCR, and toxicity analysis.

Researchers

Presenter

  • Fernando Rivera

Principal Investigators

  • Paula Jimenez

  • Pilar Garcia Alfonso

  • Encarnacion Gonzalez

  • Raquel Serrano

  • Eva Fernandez Parra

  • Monica Jorge

  • Carlos Lopez

  • Javier Gallego

  • M. Luisa Limon

  • Maria Alsina

  • Luis Lopez-Gomez

  • Maica Galan

  • Esther Falco

  • Jose Luis Manzano

Medical Centers

  • Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain

  • Hospital Universitario Virgen del Rocio, Sevilla, Spain

  • Hospital Son Llatzer, Palma De Mallorca, Spain

  • Hospital Universitario Virgen de las Nieves, Granada, Spain

  • Hospital de Valme, Seville, Spain

  • Hospital Universitario Reina Sofia, Cordoba, Spain

  • Hospital Universitari Germans Trias i Pujol, Badalona, Spain

  • Hospital Universitario del Mar, Barcelona, Spain

  • Hospital Universitario Central de Asturias, Oviedo, Spain

  • Hospital Virgen de la Salud, Toledo, Spain

  • Hospital General Universitario de Elche, Alicante, Spain

Locations

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Circulating tumor cells

  • erb-b2 receptor tyrosine kinase 2

Drug/Treatment

  • Capecitabine and oxaliplatin

  • Trastuzumab

  • Oxaliplatin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT01130337

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved